Table 1.
Baseline characteristics of SARS-CoV-2 positive patients and health and comorbid age- and sex- matched individuals SARS-CoV-2 negative.
| Characteristics | SARS-CoV-2 positive patients (n = 19) |
SARS-CoV-2 negative patients (comorbidities) (n = 8) |
SARS-CoV-2 negative patients (healthy) (n = 7) |
p value |
|---|---|---|---|---|
| Demographic | ||||
| Age (years), median IQR | 57 (50–70) | 58 (52–63.25) | 45 (36–70) | 0.175 |
| Male gender (%) | 50% | 37,5% | 43% | 0.828 |
| Comorbidities | ||||
| Hypertension (%) | 65% | 100% | ||
| Heart disease | 50% | 12,5% | ||
| Diabetes (%) | 45% | 50% | ||
| Obesity (%) | 50% | 25% | ||
| BMI, median, IQR | 28 (25–35) | 27.9 (26.9–31.7) | 0.975 | |
| Clinical characteristics of COVID-19 patients | ||||
| Days of symptoms, mean, ± sd | 13 ± 5 | – | – | |
| Hospital stays (days), mean, ± sd | 18 ± 11 | – | – | |
| Mechanical ventilation (%) | 50% | – | – | |
| Acute Kidney Injury (%) | 35% | – | – | |
| Mortality rate (%) | 10% | – | – | |
| Laboratory tests | ||||
| Creatinine, mg/dL, mean (IQR) | 1.1 ± 0.9 | – | – | |
| Lymphocyte; mm3, median (IQR) | 1100 (600–1650) | – | – | |
| Platelets; x 103/l (IQR) | 246 (217–338) | – | – | |
| RCP; mg/dL, median (IQR) | 13 (9–20) | – | – | |
| D dimer; mg/dl, median (IQR) | 1.19 (0.93–1.98) | – | – | |
| Lactate; mg/dL, median (IQR) | 2.2 (1.7–2.6) | – | – | |
| Lactate dehydrogenase, U/L (IQR) | 361 (302–434) | – | – | |
| Ferritin, ng/mL (IQR) | 608 (345–1076) | – | – | |
| Fibrinogen (mg/dLL L) | 686 (619–815 | – | – | |
| Severity | ||||
| PaO2/FiO2 ratio, median (IQR) | 205 (139–315) | – | – | |
| SOFA score | 2 (1–3) | – | – | |
|
Simplified acute physiology score 3 SAPS-3 |
47 (38–50) |
- - |
- - |
IQR interquartile range, sd standard deviation, RCP reactive C protein, SOFA sequential organ failure assessment,